Medical devices, healthcare technology and the business of care
PMA approval · P190032

FoundationOne Liquid CDx (F1 Liquid CDx)

Foundation Medicine, Inc. · Decision date Aug 26, 2020

FDA DECISIONP190032

What did the FDA approve?

FDA records P190032 as an original PMA application. The recorded decision is approval, dated Aug 26, 2020.

FDA approval order statement

Approval for the FoundationOne Liquid CDx. The device is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions (indels) in 311 genes, including rearrangements and copy number losses only in BRCA1 and BRCA2. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOne Liquid CDx cfDNA blood collection tubes included in the FoundationOne Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling for substitutions and indels to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Table 1: Companion diagnostic indicationsTumor Type Biomarker(s) Detected TherapyNon-small cell lung cancer (NSCLC) EGFR exon 19 deletions andEGFR exon 21 L858R alteration IRESSA (gefitinib)TAGRISSO (osimertinib)TARCEVA (erlotinib)Prostate cancer BRCA1, BRCA2 alterations RUBRACA (rucaparib)A negative result from a plasma specimen does not mean that the patients tumor is negative for genomic findings. Patients who are negative for the mutations listed in Table 1 should be reflexed to routine biopsy and their tumor mutation status confirmed using an FDA-approved tumor tissue test, if feasible.Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product. FoundationOne Liquid CDx is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, MA.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Aug 26, 2020

FDA source record

Regulatory record facts

Identifier
P190032
Regulatory pathway
Premarket approval application
Product code
PQP
Decision code
APPR
Decision date
Aug 26, 2020
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P190032 received

    Application receipt date recorded by FDA.

  2. P190032 · FDA decision

    APPR

  3. P190032/S032 · Related supplement

    FoundationOne Liquid CDx (F1LCDx)

Timeline entries are records held by MedtechLedger for P190032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190032

Product / regulatory recordCompanyPathwayDecision dateSource
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Foundation Medicine, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
400 Summer St., Boston, MA, 02210

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records